231 related articles for article (PubMed ID: 27802977)
1. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray RM; Quattrone D; Natesan S; van Os J; Nordentoft M; Howes O; Di Forti M; Taylor D
Br J Psychiatry; 2016 Nov; 209(5):361-365. PubMed ID: 27802977
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
3. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
4. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
5. How long should antipsychotic treatment be continued after a single episode of schizophrenia?
Emsley R; Kilian S; Phahladira L
Curr Opin Psychiatry; 2016 May; 29(3):224-9. PubMed ID: 26967313
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
7. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
8. Do antipsychotic drugs lose their efficacy for relapse prevention over time?
Leucht S; Davis JM
Br J Psychiatry; 2017 Sep; 211(3):127-129. PubMed ID: 28864750
[TBL] [Abstract][Full Text] [Related]
9. Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis.
Wunderink L
Schizophr Res; 2018 Jul; 197():65-66. PubMed ID: 29128323
[No Abstract] [Full Text] [Related]
10. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis.
Rubio JM; Schoretsanitis G; John M; Tiihonen J; Taipale H; Guinart D; Malhotra AK; Correll CU; Kane JM
Lancet Psychiatry; 2020 Sep; 7(9):749-761. PubMed ID: 32828165
[TBL] [Abstract][Full Text] [Related]
11. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
12. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
13. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
15. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
Jalenques I; Ortega V; Legrand G; Auclair C
Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.
Bosveld-van Haandel LJ; Slooff CJ; van den Bosch RJ
Acta Psychiatr Scand; 2001 May; 103(5):335-46. PubMed ID: 11380303
[TBL] [Abstract][Full Text] [Related]
18. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.
Harrow M; Jobe TH; Faull RN
Psychol Med; 2014 Oct; 44(14):3007-16. PubMed ID: 25066792
[TBL] [Abstract][Full Text] [Related]
19. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
